CTLA4 and neoplasm: In both genetic and syngeneic mice models of PDAC, combination of the FAK inhibitor VS-4718 with the chemotherapeutic agent gemcitabine and anti-PD-1 and/or anti-CTLA-4 therapy achieved a maximal response in terms of reducing tumor progression and increasing survival.